AT 301

Drug Profile

AT 301

Alternative Names: AT-301; Inactivated H5N1 influenza virion vaccine - Medigen Biotechnology Corporation

Latest Information Update: 06 Apr 2016

Price : $50

At a glance

  • Originator Medigen Biotechnology Corporation
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Influenza A virus H5N1 subtype

Highest Development Phases

  • No development reported Influenza A virus H5N1 subtype

Most Recent Events

  • 12 Nov 2013 AT 301 is available for licensing (www.medigen.com.tw/eng)
  • 05 Sep 2012 Phase-I clinical trials in Influenza-A virus H5N1 subtype (Prevention, in volunteers) in Taiwan (IM)
  • 01 Aug 2012 Preclinical trials in Influenza-A virus H5N1 subtype (Prevention) in Taiwan (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top